TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...
Cellarity announced acceptance of two oral presentations on its sickle cell disease and myelofibrosis programs during the ASH Annual Meeting.
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN Session Date and Time: December 6, 2025; 9:30 AM – 11:00 AM ...
Arabidopsis thaliana was always an unlikely candidate for the limelight. But 25 years ago, the diminutive thale cress ...
5don MSN
Israel strikes Gaza after it accuses Hamas of violating ceasefire and staging hostage discovery
Israeli strikes in Gaza killed at least nine people after it accused Hamas of violating the US-brokered ceasefire deal and ...
LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first ...
Prime Minister Benjamin Netanyahu on Tuesday ordered the Israeli military to carry out “immediate, powerful” strikes in Gaza ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEsDemonstrated selective T cell cytotoxicity against cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback